Chronological milestones to guide drug change: When should clinicians switch antidepressants?

Archives of General Psychiatry

Volumn 53, Issue 9, 1996, Pages 785-792

  Quitkein, Frederic M ^a,b   McGrath, Patrick J ^a   Stewart, Jonathan W ^a   Ocepek Welikson, Katja ^a   Taylor, Bonnie P ^a   Nunes, Edward ^a   Deliyannides, Deborah ^a   Agosti, Vito ^a   Donovan, Steven J ^a   Petkova, Eva ^a   Klein, Donald F ^a  

^a The New York Presbyterian Hospital   (United States)

^b Box 12 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; IMIPRAMINE; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; DYSTHYMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PROGNOSIS; SINGLE BLIND PROCEDURE;

EID: 9544233539     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1996.01830090031005     Document Type: Article

References (28)

1. Klein DF, Gittelman-Klein R, Ouitkin FM, Rifkin A. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, Md: Williams & Wilkins: 1980:276-283.
2. Joyce PR, Paykel ED. Predictors of drug response in depression. Arch Gen Psychiatry. 1989;46:88-89.
3. Bielski RJ, Friedel RO. Prediction ot tricydic antidepressant response Arch Gen Psychiatry 1976;33:1479-1489.
4. Katz MM, Koslow SH, Maas JW, Frazer A, Bowden CL, Casper R, Croughan J, Kocsis J, Redmond E Jr. The timing specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med. 1987;17:297-309
5. Casper RC, Katz MM, Bowden CL, Davis JM, Koslow SH, Hanin I. The pattern of physical symptom changes in major depressive disorder following teatment with amitriptyline or imipramine. J Affect Disord. 1994;31:151-164.
6. Coryell W, Coppen A, Zeigler VE, Biggs JT. Early improvement as a predictor of response to amitriptyline and nortriptyline a comparison of 2 patient samples. Psychol Med. 1982;12:135-139.
7. Stassen HH, Angst J, Delini-Stula A. Severity at baseline and onset of improvement in depression: meta-analysis of imipramine and moclobemide versus placebo. Eur Psychiatry. 1994;9129-136.
8. Katz M, Maas J, Frazer A, Koslow SH. Onset of antidepressant activity, the structure of depression and multiple drug actions. Presented at the American College of Neuropsychopharmacology Meeting; December 4, 1994; San Juan. Puerto Rico.
9. McGrath PJ, Stewart JW, Nunes EV, Ocepek-Welikson K, Rabkin JG, Quitkin KM, Klein DF. A double-blind cross over trial of imipramine and phenelzine for outpatients with treatment refractory depression. Am J Psychiatry. 1993;150(1):118-123
10. Quitkin FM, Rabkin JG, Markowitz JM, Stewart JW, McGrath PJ, Harrisen W. Use of pattern analysis to identity true drug response: a replication. Arch Gen Psychiatry. 1987;44:259-264.
11. Stewart J, Quitkin FM, Fyer A, Rifkin A, McGrath P, Liebowitz M, Rosnick L, Klein DF. Efficacy of desipramire in endogenmorphically depressed patents. J Affect Disord. 1980;2:165-176.
12. Stewart JW, Quitkin FM, McGratti PJ, Liebowitz MR, Klein DF. Efficacy of desipramine in mildly depressed patients a double-blind placebo-controlled trial. Psychopharmacol Bull. 1981;17:159-161.
13. Quitkin FM, Liebowitz MR, Stewart JW, McGrath PJ, Harrison W, Rabkin JG, Markowitz J, Davies SO. /-Deprenyl in atypical depressives. Arch Gen Psychiatry. 1984;41:777-781.
14. McGrath PJ, Quitkin FM, Harrison W, Stewart JW. Treatment of melancholia with tranylcypromine. Am J Psychiatry. 1984;141:288-289.
15. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, Rabkin JG, Tricamo E, Goetz DM, Klein DF. Antioepressant specificity in atypical depression. Arch Gen Psychiatry. 1988;45:129-137
16. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Wager SG, Nunes E, Rabkin JG, Tricamo E, Markowitz J, Klein DF. Phenelzine and imipramine in mood reactive depressives: further delineation of the syndrome of atypical depression. Arch Gen Psychiatry. 1989;46:787-793.
17. McGrath PJ, Rabkin JG, Stewart JW, Harrison W, Ouitkin FM, Markowitz J. Placebo-controlled study of mianserin in depressed outpatients. Neuropsychobiology. 1985;14:128-132.
18. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Tricamo E, Wager SG, Ocepek-Welikson K, Nunes E, Rabkin JG, Klein DF. Atypical depression, panic attacks and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry. 1990;47:935-941.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
20. Stewart JS, McGrath PJ, Rabkin JG, Quitkin FM. Atypical depression: a valid clinical entity? Psychiatr Clin North Am. 1993;16:479-495.
21. Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria (ROC) for a Selected Group of Functional Disorders. 3rd ed New York, NY: New York State Psychiatric Institute. Biometrics Research; 1977:19.
22. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry. 1985;46:53-58
23. Beasley CM, Sayler ME, Potvin JH. Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial. Int Clin Psychopharmacol. 1993;8:143-149
24. Feighner JP, Cohn JB. Double blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry. 1985;46(3, pt2):20-25.
25. Fabre LF, Crismon L. Efficacy of fluoxetine in outpatients with major depression. Curr Ther Res. 1985;37:115-123.
26. Rosenbaum JF, Fava M, Quitkin FM, McGrath PJ, Stewart JW. Time to remission of depression with acute fluoxetine treatment. Presented at the 34th Annual Meeting of the New Clinical Drug Evaluation Unit; June 3, 1994; Marco Island, Fla.
27. Heninger GR, Charmey DS, Steinberg DE. Lithium carbonate augmentation of antidepressant treatment. Arch Gen Psychiatry 1993;40:1335-1342.
28. Prange AJ, Wilson IC, Rabon AM. Enhancement of imipramine antidepressant activity by thyroid. Am J Psychiatry. 1969;126:457-469.